Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accumulated Expenses (2019 - 2025)

Biodesix (BDSX) has disclosed Accumulated Expenses for 7 consecutive years, with $767000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 88.67% year-over-year to $767000.0, compared with a TTM value of $767000.0 through Dec 2025, down 88.67%, and an annual FY2025 reading of $767000.0, down 88.67% over the prior year.
  • Accumulated Expenses was $767000.0 for Q4 2025 at Biodesix, down from $6.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.6 million in Q3 2024 and bottomed at $767000.0 in Q4 2025.
  • Average Accumulated Expenses over 5 years is $4.3 million, with a median of $4.0 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 212.91% in 2023, then plummeted 88.67% in 2025.
  • Year by year, Accumulated Expenses stood at $4.0 million in 2021, then crashed by 69.42% to $1.2 million in 2022, then surged by 212.91% to $3.9 million in 2023, then skyrocketed by 75.62% to $6.8 million in 2024, then tumbled by 88.67% to $767000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for BDSX at $767000.0 in Q4 2025, $6.9 million in Q3 2025, and $803000.0 in Q2 2025.